postmarket

Magnifying glass copy

TGA Publishes updated MDIR Guide

By Grant Bennett | 31 October, 2019
Last week, the Australian regulator, the Therapeutic Goods Administration (TGA) published an updated guidance for Australian Sponsors and Manufacturers for the reporting of adverse events in Australia (Medical device incident...
Gandalf

New Zealand WANDers towards increased device regulation

By Arthur Brandwood | 21 December, 2018
If you are WANDering about the title of this blog, yes, it’s a dreadful pun I know – but it’s that time of year. New Zealand’s Medsafe have issued a...
Uncertainty

Risk vs. Benefit FDA guidance gets to grips with uncertainty

By Arthur Brandwood | 27 September, 2018
Doing risk management in an uncertain world is why regulatory affairs are as much art as science. Innovators will continue to push the envelope of the possible while regulators will...

Search

Recent Posts

New Guidance on FDA ISO 10993-1

Sep 14, 2020

Australian Prescription Medicine Pathways – Project Orbis

Sep 1, 2020

TGA Advertisement Framework Revisions Hard at Work During Pandemic Times

Aug 31, 2020

Chemical Characterisation – no simple matter

Aug 28, 2020

Multiple Function Devices

Aug 26, 2020

Impact of COVID-19 on Medical Device Sales and Reimbursement in Australia

Aug 10, 2020

Categories

Categories

Archives

Archives

Archives

Tags

510(k) APAC Australia Biocompatibility Brexit CE CE Certificates clinical trials coronavirus COVID-19 COVID19 de novo distribution Drug EU Europe FDA guidance ISO 10993-18 IVD IVDD IVDR MDD MDR MDSAP medical device Medical Device Regulations medical devices Medicine medicines New Zealand Notified Bodies Pharmaceutical PMA PMDA postmarket private health insurance Quality Systems Reform regulatory Reimbursement SaMD Software standards TGA